RPS29P22

Across TCGA pan-cancer cohorts, RPS29P22 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPS29P22’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RPS29P22 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPS29P22 is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

HNSC, CHOL, and BRCA are the cancer types where RPS29P22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPS29P22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.120	.004	7	view →
CHOL	All	II,III,IV	+0.515	<.001	2	view →
BRCA	Female	All	+0.208	.041	2	view →
KIRC	Male	II,III,IV	−0.115	.029	2	view →
BLCA	All	III,IV	+0.385	.026	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RPS29P22–HNSC

Open the HNSC breakdown →